Inventing and “Reinventing” Under Patent Law‎


Location: 2108 Eck and Online

H Iptl Ndls Logo Cmyk Copy 2

Join us for this informative patent law event co-sponsored with Locke Lord in Chicago. RSVP here.


Welcome/Introductory Remarks (4:00 – 4:15 p.m. EDT)

Professor Mark McKenna, Notre Dame Law School ‎

The Hatch-Waxman Act: The Role of Generics in Patent Law (4:15 – 4:45 p.m. EDT)

The Hatch-Waxman Act frames the relationships between pharmaceutical companies that produce ‎generic drugs and the first-mover pharmaceutical companies who invent brand-name drugs on the ‎market. Abbreviated New Drug Applications (ANDA) filed by pharmaceutical companies who ‎wish to produce and sell generic versions may lead to questions of validity for the patent first ‎issued to the brand-name pharmaceutical company. ANDAs may also lead to negotiations ‎brought on by the exclusivity promised by the Hatch-Waxman Act. How does the Hatch-Waxman ‎Act work in practice and what are the most recent case law developments? How is the Hatch-‎Waxman Act perceived by policy-makers and might there be future revisions to it on the horizon? ‎What are the litigation trends as more and more companies increasingly become “generic ‎players”? The discussion will also explore the current Hatch-Waxman issues related to the ‎coronavirus, such as how postponements of hearings have affected regulatory stays related to the ‎approval of ANDAs for generic products.‎

Ll Sq Cmyk


  • Moderator: Erika Lietzan, William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law, University of Missouri School of Law 
  • David Abramowitz, Partner, Locke Lord‎
  • Carolyn Blessing, Partner, Locke Lord‎
  • Amanda Hollis, Partner, Kirkland & Ellis‎

BREAK‎ (4:45 – 5:00 p.m. EDT) 

Patent Incentives, Patent Litigation, and Small Molecule Drug Development [5:00 pm- 5:30pm]

Patent incentives are widely considered critical to drug development. Critics charge, however, that firms sometimes use low-quality patents to extend patent terms unduly. This talk will present empirical data on the types of patents that firms seek and how those patents are litigated,
whether in district court or at the Patent Trial and Appeal Board (PTAB). It will also discuss the important and complex public and private collaboration play in patent development.

Professor Arti Rai, Duke University School of Law

BREAK‎ (5:30  – 5:45 p.m. EDT) 

Inventions at the “Litigation” Stage: Inter Partes Review and/or District Court (5:45 – ‎6:15 p.m. EDT)
Companies and inventors developing pharmaceuticals will often strategically decide whether to ‎ask for inter partes review at the Patent Office to address patentability or to litigate patentability ‎and other issues in district court. Different results in each of these venues, often based on the ‎application of different standards of review, make these strategic decisions important for the scope ‎of patent protection and the validity of patents themselves. How is patent validity best litigated in ‎district court and what methods of advocacy are effective? What are the nuances of inter partes ‎review of which attorneys practicing before the PTAB should be aware? Is engaging in forum ‎shopping uniquely beneficial to certain claims? The discussion will also touch on novel issues that ‎have arisen in IP litigation due to the coronavirus and the need to work remotely. Having to ‎conduct depositions, for example, from multiple locations and participate in hearings and oral ‎arguments remotely are new facets of IPRs and litigation in district court. ‎

  • Moderator: David Schwartz, Professor of Law and Associate Dean of Research & Intellectual Life, ‎Northwestern University Pritzker School of Law [Moderator]‎
  • Emer Simic, Partner, Green Griffith
  • Patrick Gallagher, Partner, Duane Morris ‎
  • Judge Jo-Anne Kokoski, Patent Trial and Appeal Board ‎

Concluding Remarks

Professor Stephen Yelderman, Notre Dame Law School